Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 9—September 2021
Synopsis

Epidemiology, Clinical Features, and Outcomes of Coccidioidomycosis, Utah, 2006–2015

Adrienne CareyComments to Author , Morgan E. Gorris, Tom Chiller, Brendan Jackson, Wei Beadles, and Brandon J. Webb
Author affiliations: University of Utah School of Medicine, Salt Lake City, Utah, USA (A. Carey); Los Alamos National Laboratory, Los Alamos, New Mexico, USA (M. Gorris); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (T. Chiller, B. Jackson); Utah Department of Health, Salt Lake City (W. Beadles); Intermountain Healthcare, Salt Lake City (B. Webb); Stanford University School of Medicine, Palo Alto, California, USA (B. Webb)

Main Article

Table 1

Demographic and clinical data from coccidioidomycosis cases identified in the Intermountain Healthcare system, Utah, USA, 2006–2015*

Variables No. (%)
Total patients
364
Demographics
Age, y, median (IQR) 61 (44–72)
Pediatric <18 y 13 (3.6)
Male sex
201 (55.2)
Race
American Indian 5 (1.4)
Asian 2 (0.5)
Black 1 (0.3)
Hispanic 20 (5.5)
Pacific Islander 9 (2.5)
Unknown 7 (1.9)
White
320 (87.9)
Coexisting conditions/medical factors
Charlson comorbidity score, median (IQR) 2 (0–4)
Diabetes mellitus 81 (22.3)
Hepatic disease 61 (16.8)
Chronic pulmonary disease 144 (39.6)
Connective tissue disease 27 (7.4)
Congestive heart failure 53 (14.6)
Neurologic disease 52 (14.3)
Renal disease 45 (12.4)
History of malignancy 76 (20.9)
Hematopoietic stem cell transplant 2 (0.5)
Solid organ transplant 2 (0.5)
Any immunosuppressive medication 27 (7.4)
Corticosteroids 25 (6.9)
Anti-TNF 3 (0.8)
Antimetabolite 2 (0.5)
Chemotherapy
4 (1.1)
Laboratory test results
Lymphopenia, absolute lymphocyte count <500 12 (3.3)
Lymphopenia value at diagnosis, absolute lymphocyte count, median (IQR)
300 (300–400)
Outcomes
Coccidioidomycosis-related hospital admission 154 (42.3)
Hospital length of stay, d, median (IQR) 0 (0–5)
42-d all-cause mortality 20 (5.5)
1-y all-cause mortality
33 (9.1)
Case classification
Proven 192 (52.7)
Probable 172 (47.3)

*Values are no. (%) except as indicated. IQR, interquartile range; TNF, tumor necrosis factor.

Main Article

Page created: June 09, 2021
Page updated: August 17, 2021
Page reviewed: August 17, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external